CSPC Innovation Pharmaceutical (SHE:300765) incurred an attributable loss of 26.9 million yuan in the first quarter, compared with an attributable profit of 79.1 million yuan a year prior, a Wednesday Hong Kong filing by parent CSPC Pharmaceutical (HKG:1093) said.
Loss per share in the quarter was 0.0192 yuan, while the company made earnings per share of 0.0676 yuan in the first quarter of 2024.
The pharmaceutical company saw a 9.9% drop in revenue to 472 million yuan in the three months from 524.1 million yuan in the year-ago period.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。